StockData
XTL Biopharmaceuticals Ltd logo

XTL Biopharmaceuticals Ltd (XTLB) stock

XTLBNasdaqPharmaceutical Preparations
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 30, 2026Score 0/30
$1.54−0.08 (-4.94%)

Close on Nov 18, 2026Market cap $14.57MP/E –Yield –

XTL Biopharmaceuticals gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

For fiscal 2024 it was $3.00K.

Annual gross profit

PeriodPeriod endValueChange
FY2024Dec 31, 2024$3.00K–

More XTL Biopharmaceuticals figures

See a number that looks wrong?